Hypertrophic Cardiomyopathy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hypertrophic Cardiomyopathy – Drugs In Development, 2024 report and make more profitable business decisions.
Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise; sensation of rapid, fluttering or pounding heartbeats; and heart murmur. Hypertrophic cardiomyopathy usually is inherited. Treatment includes beta blockers, calcium channel blockers, and blood thinners.
The Hypertrophic Cardiomyopathy drugs in development market research report provide comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hypertrophic Cardiomyopathy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 40 molecules, with 37 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hypertrophic Cardiomyopathy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hypertrophic Cardiomyopathy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hypertrophic Cardiomyopathy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Algomedix IncBioMarin Pharmaceutical Inc
Bristol-Myers Squibb Co
C&C BioPharma LLC
Cardior Pharmaceuticals GmbH
Cytokinetics Inc
DiNAQOR AG
Edgewise Therapeutics Inc
Genome Biologics UG
Haya Therapeutics SA
Hemostemix Inc
Igia Pharmaceuticals Inc
Imbria Pharmaceuticals Inc
Invivosciences Inc
Jaan Biotherapeutics LLC
Ji Xing Pharmaceuticals Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johns Hopkins University
Lead Discovery Center GmbH
Lexeo Therapeutics Inc
Novartis AG
Novo Nordisk AS
Saliogen Therapeutics Inc
Solid Biosciences Inc
StrideBio Inc
Tenaya Therapeutics Inc
Toa Eiyo Ltd
U.S. Department of Veterans Affairs
Washington University School of Medicine
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hypertrophic Cardiomyopathy reports